...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Characterization of porin expression in Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems
【24h】

Characterization of porin expression in Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems

机译:肺炎克雷伯菌肺炎克雷伯菌酶(KPC)产生的肺炎克雷伯菌中孔蛋白表达的特征鉴定出最易发生大肠菌素和碳青霉烯结合的分离株

获取原文
获取原文并翻译 | 示例
           

摘要

We characterized carbapenem resistance mechanisms among 12 Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (referred to here as KPC K. pneumoniae) clinical isolates and evaluated their effects on the activity of 2-and 3-drug combinations of colistin, doripenem, and ertapenem. All isolates were resistant to ertapenem and doripenem; 75% (9/12) were resistant to colistin. Isolates belonged to the ST258 clonal group and harbored blaKPC-2, blaSHV-12, and blaTEM-1. As determined by time-kill assays, doripenem (8 μg/ml) and ertapenem (2 μg/ml) were inactive against 92% (11/12) and 100% (12/12) of isolates, respectively. Colistin (2.5 μg/ml) exerted some activity (range, 0.39 to 2.5 log10) against 78% (7/9) of colistin-resistant isolates. Colistin-ertapenem, colistin-doripenem, and colistin-doripenem-ertapenem exhibited synergy against 42% (5/12), 50% (6/12), and 67% (8/12) of isolates, respectively. Expression of ompK35 and ompK36 porins correlated with each other (R2= 0.80). Levels of porin expression did not correlate with colistin-doripenem or colistin-ertapenem synergy. However, synergy with colistin-doripenem- ertapenem was more likely against isolates with high porin expression than those with low expression (100% [8/8] versus 0% [0/4]; P=0.002). Moreover, bactericidal activity (area under the bacterial killing curve) against isolates with high porin expression was greater for colistin-doripenem-ertapenem than colistin-doripenem or colistin-ertapenem (P < 0.049). In conclusion, colistin-carbapenem combinations may provide optimal activity against KPC K. pneumoniae, including colistin-resistant isolates. Screening for porin expression may identify isolates that are most likely to respond to a triple combination of colistin-doripenem-ertapenem. In the future, molecular characterization of KPC K. pneumoniae isolates may be a practical tool for identifying effective combination regimens.
机译:我们表征了12种生产肺炎克雷伯菌肺炎克雷伯菌(KPC)肺炎克雷伯菌(此处称为KPC肺炎克雷伯菌)临床分离株中的碳青霉烯耐药机制,并评估了它们对大肠菌素,多利培南,和厄他培南。所有分离株均对厄他培南和多利培南具有抗性。 75%(9/12)对粘菌素有抗性。分离株属于ST258克隆组,包含blaKPC-2,blaSHV-12和blaTEM-1。通过时间杀灭试验确定,多立培南(8μg/ ml)和厄他培南(2μg/ ml)分别对92%(11/12)和100%(12/12)的分离物无效。 Colistin(2.5μg/ ml)对耐大肠菌素的78%(7/9)分离株表现出一定的活性(范围为0.39至2.5 log10)。 Colistin-ertapenem,colistin-doripenem和colistin-doripenem-ertapenem分别对42%(5/12),50%(6/12)和67%(8/12)的分离株表现出协同作用。 ompK35和ompK36孔蛋白的表达相互关联(R2 = 0.80)。孔蛋白表达水平与大肠粘菌素-多利培南或大肠粘菌素-大萜素协同作用无关。然而,与低表达的分离株相比,与大肠菌素-多胺培南-二萜萜的协同作用更有可能对抗高孔蛋白表达的分离株(100%[8/8]比0%[0/4]; P = 0.002)。而且,大肠菌素-多柔比南-厄他培南对具有高孔蛋白表达的分离物的杀菌活性(大肠菌素曲线下的面积)比大肠菌素-多利培南或大肠菌素-厄他培南大(P <0.049)。总之,大肠菌素-卡巴培南组合可能提供针对KPC肺炎克雷伯菌的最佳活性,包括耐大肠菌素的分离株。筛选孔蛋白表达可能会鉴定出最有可能对大肠菌素-多利培南-厄他培南的三联体反应的分离株。将来,KPC肺炎克雷伯菌分离株的分子表征可能是鉴定有效联合方案的实用工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号